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Background. We previously suggested that infection with the human T-lymphotropic virus type 1 (HTLV-1)
subtype C is associated with bronchiectasis among Indigenous Australians. Bronchiectasis might therefore result
from an HTLV-1-mediated inflammatory process that is typically associated with a high HTLV-1 proviral load
(PVL). Human T-lymphotropic virus type 1 PVL have not been reported for Indigenous Australians.
Methods. Thirty-six Indigenous adults admitted with bronchiectasis from June 1, 2008, to December 31, 2009
were prospectively recruited and matched by age, sex, and ethno-geographic origin to 36 controls. Case notes and
chest high-resolution computed tomographs were reviewed, and pulmonary injury scores were calculated. A PVL
assay for the HTLV-1c subtype that infects Indigenous Australians was developed and applied to this study. Clinical,
radiological, and virological parameters were compared between groups and according to HTLV-1 serostatus.
Results. Human T-lymphotropic virus type 1 infection was the main predictor of bronchiectasis in a multivar-
iable model (adjusted risk ratio [aRR], 1.84; 95% confidence interval [CI], 1.19–2.84; P = .006). Moreover, the median
HTLV-1c PVL (interquartile range) for cases was >100-fold that of controls (cases, 0.319 [0.007, 0.749]; controls,
0.003 [0.000, 0.051] per 100 peripheral blood lymphocytes; P = .007), and HTLV-1c PVL were closely correlated
with radiologically determined pulmonary injury scores (Spearman’s rho = 0.7457; P = .0000). Other predictors of
bronchiectasis were positive Strongyloides serology (aRR, 1.69; 95% CI, 1.13–2.53) and childhood skin infections
(aRR, 1.62; 95% CI, 1.07–2.44). Bronchiectasis was the major predictor of death (aRR, 2.71; 95% CI, 1.36–5.39;
P = .004).
Conclusions. These data strongly support an etiological association between HTLV-1 infection and bronchiec-
tasis in a socially disadvantaged population at risk of recurrent lower respiratory tract infections.
Keywords. Australia; bronchiectasis; HTLV-1; HTLV-1 proviral load; Indigenous; pulmonary disease;
Strongyloides stercoralis.
The human T-lymphotropic virus type 1 (HTLV-1) is
an oncogenic retrovirus that infects at least 5–10 million
people, most of whom reside in developing countries
[1]. Among the many clusters of high HTLV-1 ende-
micity worldwide is a small endemic focus in central
Australia [1],where 7.2%–13.9% of the Indigenous pop-
ulation is infected [2, 3]. In <10% of HTLV-1 carriers,
infection is complicated by noninfective sequelae
including adult T-cell leukemia/lymphoma [4, 5] and
inflammatory disorders, the prototype of which is HTLV-
1-associated myelopathy/tropical spastic paraparesis
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(HAM/TSP) [5]. In resource-limited areas, infectious complica-
tions also contribute to HTLV-1-related morbidity and mortal-
ity [5]. People infected with HTLV-1 are at increased risk of
symptomatic and life-threatening complicated strongyloidiasis
[6], and a severe exudative eczema, infective dermatitis, pre-
dominantly affects HTLV-1 carriers from a lower socioeconom-
ic background [5, 7].
Human T-lymphotropic virus type 1-associated inflammatory
syndromesmay affect organ systems that are remote from the cen-
tral nervous system [5]. Pulmonary involvement, for example, af-
fects all lung compartments [8–11] and has been reported in as
many as 30% of asymptomatic people with HTLV-1 infection
[10]. However, clinically significant pulmonary disease is uncom-
mon among people infected with HTLV-1 in developed countries
[12, 13]. In contrast, we recently suggested that HTLV-1 infection
in an impoverished Indigenous population in central Australia
was associated with multilobar bronchiectasis, and bronchiectasis
was a major cause of early mortality among Indigenous adults
[14]. In this retrospective study, differences in presentation and
outcomes were compared among patients with established bron-
chiectasis according toHTLV-1 serostatus. Consequently, wewere
unable to determine risk relative to a control group without bron-
chiectasis or to study the possible pathological basis of disease.
Among socially disadvantaged Indigenous Australians, bron-
chiectasis might result from an HTLV-1-mediated inflammato-
ry process, a predisposition to repeated lower respiratory tract
infections (LRTIs), or a combination of these factors. A major
determinant of HTLV-1-associated inflammatory diseases, such
as HAM/TSP, is thought to be a high HTLV-1 antigen load [15].
The HTLV-1 antigen load is reflected in the integration of
HTLV-1 provirus into peripheral blood lymphocytes (PBLs),
the quantification of which is defined as the HTLV-1 proviral
load (PVL). Unfortunately, we were unable to quantify
HTLV-1 PVL for subjects whose clinical details were described
in our previous study [14]. The highly divergent HTLV-1c
strains that infect Indigenous Australians have since been better
characterized [16]. A method for determining the PVL of these
HTLV-1c strains has subsequently been developed, and this
method was applied to the present study. Therefore, the pur-
pose of this case-control study was to further define the risk
of bronchiectasis among Indigenous adults who were infected
with HTLV-1c and to determine whether higher HTLV-1c
PVL or more frequent LRTIs contribute to this risk.
METHODS
The Study Setting
Most Indigenous residents of central Australia reside in condi-
tions of considerable socioeconomic disadvantage in isolated
remote communities or overcrowded “town camps,” which
have poor amenities and limited refuse disposal. A single, well
resourced, community-based hospital, Alice Springs Hospital
(ASH), serves this region of 1 000 000 km2. The hospital
operates in a complex cross-cultural environment; rates of
self-discharge are the highest reported worldwide, and many
patients seek help from traditional healers before attending
ASH [17]. No attempt has been made to control HTLV-1 trans-
mission among Indigenous Australians.
Recruitment
Cases were Indigenous adults (age≥15 years) with bronchiectasis
who were admitted to ASH for >48 h with an infective exacerba-
tion from June 1, 2008 to December 31, 2009. Diagnosis was
made by chest high-resolution computed tomography (HRCT)
(34), bronchoscopy (1), and bronchography (1). Mortality rates
among Indigenous Australians with bronchiectasis are high. In
our previous study, for example, 34.2% of our cohort died during
the study period [14]; therefore, the present study includes only
18 subjects whose clinical details were presented previously [14].
Controls were Indigenous adults admitted during the same pe-
riod for cardiological investigations (12), trauma (10), general
surgery (9), and missed dialysis (3) who had no evidence of
LRTIs and no dermatological or neurological symptoms that
might be attributable to HTLV-1 infection. Chest x-rays were re-
viewed for all potential control patients, and those with pulmo-
nary abnormalities were excluded. A research team member
(S. J.) whowas unaware of the HTLV-1 serostatus was responsible
for recruitment. All patients gave written informed consent.
Matching of Controls
Human T-lymphotropic virus type 1 seroprevalence varies with
age, gender, and place of residence [1]. Cases were therefore
matched to controls 1 : 1 according to age (age of case ±10
years), gender, and primary language, which was determined
by 2 Aboriginal Research Officers. Subjects were then matched
by another research team member (E. G.). All were unaware of
the HTLV-1 serostatus of enrolled patients.
Clinical data were extracted from case notes from date of first
admission to date of recruitment using a standardized data-
collection form. For cases, data are presented to date of diagnosis.
Results for all microbiological tests, full blood examinations, radi-
ology, and other relevant investigations were also extracted. Re-
sults were recorded for sputum cultures performed during
separate admissions >2 weeks apart. Persistent eosinophilia was
defined as an eosinophil count >0.7 × 109/L for >12 months.
Strongyloides stercoralis serological status was determined using
an in-house enzyme-linked immunosorbent assay based on anti-
gen extracts of Strongyloides ratti, which is highly sensitive and
specific. Results were recorded as positive, equivocal, or negative
according to predetermined optical density cutoffs.
Pulmonary Injury Scores
High-resolution computed tomography chest images for 33
cases were available, and these were reviewed remotely using
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the Picture Archiving and Communication System with Intele-
viewer software by 2 consultant radiologists (V. A., S. H.) in Ad-
elaide, 1500 km from ASH. Both radiologists were blinded to
HTLV-1 serostatus. A “pulmonary injury score” was calculated
using a system modified from Bhalla et al [18]. Each lobe
was scored independently for bronchiectasis severity (0–3),
bronchial wall thickening (0–3), mucus plugging/centrilobular
nodules (0,1), sacculation (0,1), parenchymal changes of
ground-glass density (0,1), and air-trapping/emphysema (0,1).
A maximal score of 10 could therefore be assigned to each
lobe. A score of 10 was also assigned to lobes with complete col-
lapse/cicatrisation. The lingular segment of the left upper lobe
was regarded as a separate lobe. Chest HRCTs for an additional
8 HTLV-1 carriers without bronchiectasis were similarly scored.
These included 2 controls (bronchiectasis previously excluded)
and 6 other patients (assessed but excluded as controls due to
intercurrent LRTIs).
HTLV-1 Serologic and Molecular Studies
Peripheral blood buffy coats (PBBCs) were transferred to Insti-
tut Pasteur, Paris, where analyses were performed blinded to the
patient’s clinical state. Plasma HTLV-1 antibodies were detect-
ed, and titers were determined using a 2-fold endpoint dilution
method by particle agglutination (PA) (Serodia HTLV-1; Fujir-
ebio, Tokyo, Japan). All samples for which PA tests were posi-
tive or borderline were tested by confirmatory Western blot
assay (HTLV-I/II Blot2.4; MP Biomedicals Asia Pacific Pty.
Ltd., Singapore).
High molecular weight DNAwas extracted and HTLV-1 PVL
was determined by SYBR Green real-time polymerase chain re-
action (PCR). This assay was performed in 20 μL PCR mixture
volume consisting of 2× Quantitect SYBR Green Master Mix
(QIAGEN) containing HotstartTaq DNA polymerase, 150 nM
of each oligonucleotide primer, and 4 μL of DNA extracted
from PBBCs. In parallel, a reference curve was obtained from
scalar dilution of cloned PCR product (from 1010 to 0.1 copies
of HTLV-1 Px genomic region). Details of HTLV-1 Px gene am-
plification were as follows: 1 cycle of 10 min at 95°C (hot-start
PCR) and 45 cycles in 3 steps each (95°C for 30 s, 56°C for 30 s,
72°C for 30 s). Human T-lymphotropic virus type 1 Px primer
sequences designed to specifically amplify HTLV-1c were as fol-
lows; PxCfor: 5′ CAC ACC GTC AAG CAC AGA TT 3′ and
PxCrev: 5′ TCT CCA TAC ACG TAG ACT GGA T 3′. Ampli-
cation using these primers yielded a 184-base pair Px fragment.
All standard dilutions and samples from patients were run in
duplicate. SYBR Green real-time PCR for a single copy host
cell gene (HLA-DQ alpha) was used to normalize the genomic
DNA input. Primers used were as follows: GH26; 5′ GTG CTG
CAG GTG TAA CTT GTA CCA G 3′ and GH27: 5′ GGA TCC
GGTAGC AGC GGTAGA GTT G 3′ [19]. Human T-lympho-
tropic virus type 1 PVLs are expressed as number of proviral
copies per 102 PBLs. The sensitivity of the method used is 1
copy of proviral DNA per 104 PBL. DNA was not available
for 1 HTLV-1-seropositive case.
The study was approved by the Central Australian Human
Research Ethics Committee.
Statistical Analysis
Categorical variables were compared using a χ2 test or Fisher’s
Exact test, as appropriate. Continuous variables were assessed
for significant departures from normality. Normally distributed
variables were summarized using mean and standard deviation
and compared using a t test. Skewed variables were summarized
using median and interquartile range (IQR) and compared
using a Wilcoxon rank-sum test.
Predictors of bronchiectasis and death were analyzed using
unadjusted and adjusted Poisson regression with robust stan-
dard errors [20]. Direct modeling of relative risk (RR) using a
Poisson approach was preferred over RR estimation via odds ra-
tios from logistic modeling due to the relative frequency of both
outcome variables (50% of the sample recorded the bronchiec-
tasis event, and 36% recorded a mortality event). Candidate pre-
dictors for inclusion in adjusted modeling were identified by (1)
their clinical and biological importance and (2) predictor per-
formance on unadjusted modeling. Colinearity and interactions
between model covariates were examined using a likelihood
ratio test. For the modeling of both outcome variables, a link
test was used to determine specification error, whereas overall
goodness of fit was assessed using both visual examination of
residuals with a likelihood-ratio test and a Pearson goodness-
of-fit test. For each outcome variable, we used an Akaike Infor-
mation Criterion to assist in identifying which particular
combination of explanatory variables in any 1 multivariate
model returned estimates that best fit the observed data.
Mortality events were obtained from the hospital patient man-
agement system until 30th June 2012. For all analyses, P < .05
was considered significant. All analyses were undertaken
using Stata, version 12 (StataCorp, College Station, TX).
RESULTS
A total of 47 patients with bronchiectasis (HTLV-1 seropositive,
33; 70.0%) met the inclusion criteria and 36 (76.6%) were re-
cruited to the study. Eleven patients (men, 8; women, 3) with
a mean age of 47 ± 9 years were discharged before consent
could be obtained in their primary languages. This was due to
our inability to find an appropriate interpreter in 9 cases and
self-discharge in 2 cases. Human T-lymphotropic virus type 1
serology was performed for each patient who was not recruited;
8 (72.7%) were HTLV-1 seropositive. The characteristics of pa-
tients who were not recruited were therefore similar to those
who consented to study participation (Table 1). Cases and con-
trols were well matched with regards to age and gender. In
adulthood, cases were more likely to dwell in the Alice Springs
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township (Table 1), less likely to require admission for harmful
alcohol consumption, but more likely to have respiratory failure
(Table 1) and echocardiographic findings consistent with pul-
monary disease (Table 1).
Risk Factors for Bronchiectasis
Human T-lymphotropic virus type 1 infection was more com-
mon among cases (25 of 36; 69.4%) than controls (15 of 36;
41.7%) (P = .018) (Table 2), and this was predictive of bron-
chiectasis in a multivariable model (adjusted risk ratio [aRR],
1.84; 95% confidence interval [CI], 1.19–2.84; P = .006)
(Table 3). The median HTLV-1c PVL (IQR) for cases was
>100-fold higher than that of controls (cases, 0.319 [0.007,
0.749]; controls, 0.003 [0.000, 0.051] per 100 PBL; P = .007)
(Table 2) (Figure 1). Each unit increase in HTLV-1c PVL was
associated with 1.21 times the risk of bronchiectasis (Table 3).
Higher pulmonary injury scores were significantly correlated
with higher HTLV-1c PVL (Figure 2). Higher HTLV-1
antibody titers, a persistent eosinophilia, positive or equivocal
Strongyloides serology, and skin infections were also associated
with bronchiectasis on univariable analysis. Positive or equivo-
cal Strongyloides serology and childhood skin infections re-
mained predictive of bronchiectasis in a multivariable model
(Table 3).
Cases were more likely to have been admitted previously with
probable HTLV-1-related conditions (Table 4). These condi-
tions included infective dermatitis (3), complicated strongyloi-
diasis unresponsive to treatment with thiabendazole (2),
inflammatory pericarditis for which no other cause was identi-
fied (1), and recurrent uveitis (1). One patient with complicated
strongyloidiasis was also admitted with infective dermatitis. Pa-
tients with pericarditis and uveitis were both ataxic; however,
clinical criteria for HAM/TSP were not met.
Admissions for LRTIs
A total of 1161 admissions were reviewed, including 122 admis-
sions in childhood (cases, 57; controls, 65) and 1039 in adult-
hood (cases, 285; controls, 754). Twelve cases and 13 controls
were admitted in childhood with 35 and 28 LRTI episodes, re-
spectively; however, only 1 case required an intensive care ad-
mission. Six cases were diagnosed with bronchiectasis in
Table 1. Patient Characteristics and Echocardiographic Find-
ings for Indigenous Adults With Bronchiectasis and Their
Matched Controlsa
Characteristic Cases
(n= 36)
Controls
(n= 36)
P
Value
Sex (male/female) (n) 25/11 25/11 1.000
Age at recruitment (years)
(mean ± SE)
43.5 (11.9) 46.1 (12.6) .384
Residence in childhoodb (n, %)
Urban 1 (4.4) 4 (21.1) .096
Remote 22 (99.7) 15 (78.9)
Residence in adulthood (n, %)
Urban 17 (47.2) 8 (22.2) .026
Remote 19 (52.8) 28 (77.8)
Comorbidities (n, %)
Diabetes 9 (25.0) 16 (44.4) .083
Tobacco 14 (38.9) 20 (55.6) .157
Alcohol 20 (55.6) 28 (77.8) .046
Asthma 6 (16.7) 2 (5.6) .260
COPD 4 (11.1) 1 (2.8) .357
Ischemic heart disease (n, %) 4 (11.1) 11 (30.6) .079
Congestive cardiac failure 2 (5.6) 4 (11.1) .674
Chronic liver disease 4 (11.1) 3 (8.3) 1.000
Respiratory failure 14 (38.9) 0 (0.0) <.001
Right heart failure 5 (13.9) 0 (0.0) .054
Echocardiography (n, %) 32 (88.9) 21 (58.3)
Dilated right ventricle 13 (40.6) 0 (0.0) .001
Tricuspid regurgitation 10 (31.3) 1 (4.8) .035
Pulmonary hypertension 13 (43.3) 0 (0.0) <.001
Abbreviations: Alcohol, harmful alcohol consumption; COPD, chronic
obstructive pulmonary disease; SE, standard error; Tobacco, tobacco smoker.
a Continuous variables are summarized using mean and SE.
b Place of residence in childhood could be ascertained for 23 cases and 19
controls.
Table 2. Results of Infection-Related Investigations for Indige-
nous Adults With Bronchiectasis and Their Matched Controlsa
Cases
(n= 36)
Controls
(n= 36)
P Value
HTLV-1 Studies
WB positive (n, %) 25 (69.4) 15 (41.7) .018
PVL (per 100 PBL)
(median, IQR)
0.319 (0.007,
0.749)
0.003 (0.000,
0.051)
.007
Ab titer (log units)
(mean ± SE)
8.53 (6.93,
9.92)
5.55 (4.85,
7.62)
.0035
Strongyloides Serologyb (n, %)
Positive 15 (41.7) 4 (16.0) <.001
Negative 11 (30.6) 20 (80.0)
Equivocal 10 (27.8) 1 (4.0)
Sputum Cultures
(median, IQR)
3 (2, 6)d 3 (2,7) .814
Haemophilus
influenzae
1 (0, 3)d 0 (0, 1) .058
Number of pathogens 2.7 (3.9)d 1.2 (2.3) .023
Eosinophiliac (n, %) 22 (61.1) 10 (27.8) .004
Abbreviations: Ab, HTLV-1 antibody titer; HTLV-1, human T-lymphotropic virus
type 1; IQR, interquartile range; PBL, peripheral blood lymphocytes; PVL,
HTLV-1c proviral load; SE, standard error; WB, Western blot.
a Continuous variables are summarized using mean and SE or median and IQR
as appropriate.
b Strongyloides serology performed for 36 cases and 25 controls.
c Eosinophils >0.7 × 109/L for >12 months.
d Pathogens isolated from sputum specimens cultured prior to diagnosis with
bronchiectasis.
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childhood. The age of first admission and the numbers of total
admissions, LRTI admissions, and LRTI admissions requiring
intensive care did not differ between groups (Table 4).
In adulthood, 21 cases and 25 controls were admitted with
110 and 82 LRTIs, respectively. These resulted in an intensive
care admission for 5 cases and 4 controls. Cases were signifi-
cantly younger when first admitted with an adult LRTI
(Table 4). There were no significant differences in the numbers
of adult LRTI admissions or the number of associated intensive
care admissions between cases and controls (Table 4).
Respiratory Pathogens
Respiratory pathogens were not more likely to be cultured from
children who were subsequently diagnosed with bronchiectasis
(Table 4). Including pathogens isolated in adulthood, 53 and 45
respiratory pathogens were cultured from the sputum of 15
cases prior to diagnosis with bronchiectasis and from14 controls,
respectively. Among subjects whose sputum cultures yielded a
respiratory pathogen, these were more often isolated from
cases (Table 2). Pathogens isolated from HTLV-1-seropositive-
patients included Mycobacterium tuberculosis (case, 1; control,
1) and Mycobacterium avium/intracellulare complex (case, 1).
Severe pneumonia due to Nocardia sp preceded the develop-
ment of bronchiectasis in 1 HTLV-1-uninfected case with a
history of harmful alcohol consumption.
Mortality
Twenty cases (55.5%) and 7 controls (19.4%) died during
208.18 years of follow-up (P = .028). Although cases died at a
younger age, this difference was not significant (cases,
48.4 ± 12; controls, 58.9 ± 10.7; P = .052). Among patients
whose cause of death could be ascertained, respiratory compli-
cations were responsible for the deaths of 16 of 17 bronchiecta-
sis cases and 1 of 7 controls (P = .205). Bronchiectasis was
strongly associated with death in a multivariable model (aRR,
2.71; 95% CI, 1.36–5.39; P = .004) (Table 5).
DISCUSSION
The adult Indigenous population of central Australia has the
highest reported prevalence of bronchiectasis worldwide [14],
yet identifying the responsible etiological conditions has proven
difficult. Measles and tuberculosis, which are frequent causes of
bronchiectasis in developing countries, are rare; cystic fibrosis
Table 3. Univariable and Multivariable Predictors of
Bronchiectasisa
Univariable Predictors Multivariable Predictors
RR 95% CI P
Value
RR 95% CI P
Value
HTLV-1 Studies
WB 3.79 2.23–6.42 .000 1.84 1.19–2.84 .006
Ab titerb 1.18 1.05–1.32 .006 . . . . . . . . .
PVLc 1.21 1.08–1.36 .001 . . . . . . . . .
Eosinophiliad 1.96 1.21–3.19 .006 . . . . . . . . .
Strongyloidese
Positive 2.23 1.31–3.79 .003 1.69 1.13–2.53 .011
Equivocal 2.56 1.53–4.28 .000 1.83 1.18–2.82 .006
Skin Infections
Childhoodf 3.77 2.36–6.03 .000 1.62 1.07–2.44 .022
Adulthoodf 1.86 1.24–2.78 .003 . . . . . . . . .
Scabies 1.74 1.04–2.92 .036 . . . . . . . . .
IDH 2.09 1.63–2.68 .000 . . . . . . . . .
HTLV-1-
associated
conditionsg
2.24 1.71–2.94 .000 . . . . . . . . .
Haemophilus
influenzaeh
1.09 1.03–1.14 .001 . . . . . . . . .
Alcoholi 0.63 0.40–0.97 .037 . . . . . . . . .
Abbreviations: Ab, HTLV-1 antibody titer; CI, confidence interval; HTLV-1,
human T-lymphotropic virus type 1; IDH, HTLV-1-associated infective
dermatitis; RR, relative risk; PVL, proviral load; WB, Western blot.
a Multivariable predictors were adjusted for the covariates listed in the table.
b Increased risk per 1 log increase in antibody titer.
c Increased risk of bronchiectasis per unit increase in HTLV-1c proviral load.
d Eosinophils > 0.7 × 109/L for at least 12 months.
e Strongyloides serology result.
f Admission specifically for the treatment of a skin infection.
g Infective (infective dermatitis, 3; complicated strongyloidiasis, 2) and
inflammatory (uveitis, 1; pericarditis, 1) conditions likely to be HTLV-1
associated.
h Haemophilus influenzae isolated from sputum prior to a formal diagnosis of
bronchiectasis.
i Harmful alcohol consumption.
Figure 1. Human T-lymphotropic virus type 1 (HTLV-1) subtype C proviral
loads for cases and controls. Box plot depicting median (interquartile range
[IQR]) HTLV-1 proviral loads for 24 bronchiectasis cases and 15 controls.
Human T-lymphotropic virus type 1 subtype C proviral load expressed as
proviral copies per 100 peripheral blood lymphocytes. Data are logarithmi-
cally transformed for clarity of presentation.
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has not been described; and other causes, such as immunoglob-
ulin deficiency, are uncommon [14, 21]. Therefore, previous
pneumonia is thought to be the cause of bronchiectasis in
>90% of childhood cases [21]. In contrast, the development of
bronchiectasis in our adult cohort was seldom preceded by an
identifiable precipitant. A diagnosis of bronchiectasis was not
made until adulthood in >80% of cases and no respiratory path-
ogens were isolated from nearly 60% of cases prior to diagnosis.
Risk of LRTIs was high in both groups; however, there were no
differences between cases and controls in the number of admis-
sions with LRTIs or their requirement for intensive care. Higher
HTLV-1 seropositivity rates and HTLV-1 PVL among cases
suggest that an HTLV-1-mediated inflammatory process
might contribute to pulmonary disease in our study population.
Pulmonary involvement has been frequently described
among HTLV-1 carriers elsewhere. Radiological abnormalities
are found in one-half of Japanese patients with HAM/TSP
[22] and 30% of asymptomatic HTLV-1 carriers [10]. These
include alveolitis [8], interstitial pneumonia [8, 23], chronic
bronchiolitis/bronchitis [9, 11], and bronchiectasis [10, 11].
Therefore, all lung compartments may be involved; however,
airway inflammation seems to be particularly frequent [10,
11]. Consistent with these radiological findings, histopatholog-
ical studies reveal infiltration of bronchiole walls by lympho-
cytes [24], which may result in their partial occlusion [25].
Small airway inflammation might contribute to a higher inci-
dence of self-reported asthma among HTLV-1 carriers in the
United States [13], yet significant pulmonary disease is an un-
common feature of HTLV-1 infection in developed countries
[12, 13]. In contrast, HTLV-1 infection nearly doubled the
risk of presenting with bronchiectasis among Indigenous Aus-
tralians in the present study. In our previous retrospective study,
bronchiectasis was more extensive, ground glass opacities were
more often present at chest HRCT, and a pathogen was less like-
ly to be isolated from sputum during an acute exacerbation of
bronchiectasis among HTLV-1 carriers. These observations
suggest that a diffuse inflammatory process that is associated
with HTLV-1 infection might contribute to the development
of bronchiectasis in our patient population [14].
The risk of inflammatory disorders, such as HAM/TSP [5], is
associated with high HTLV-1 PVL in PBLs [5]. The pathophys-
iological processes that result in HAM/TSP have not been fully
elucidated, but they may include the release of proinflammatory
cytokines from HTLV-1-infected cells [26] and injury resulting
from the immune response to a high HTLV-1 antigen load that
Figure 2. Pulmonary injury scores versus human T-lymphotropic virus
type 1 (HTLV-1) subtype C proviral load. Correlation between HTLV-1c
proviral loads (proviral copies per 100 peripheral blood lymphocytes) and
pulmonary injury scores, which were calculated by applying a predeter-
mined scoring system to chest high-resolution computed tomography for
29 HTLV-1-seropositive patients (bronchiectasis, 21; no bronchiectasis,
8). Spearman’s rho = 0.7457; Prob > |t| = 0.0000.
Table 4. Details of Previous Admissions for Indigenous Adults
With Bronchiectasis and Their Matched Controlsa
Cases
(n= 36)
Controls
(n= 36)
P
Value
Skin Conditions (n, %)
Any admission 9 (25.0) 0 (0.0) .002
Childhood admissionb 6 (30.0) 0 (0.0) .022
HTLV-1-associated
conditionsc (n, %)
6 (16.7) 0 (0.0) .025
Childhood
Any admission (n, %) 20 (55.6) 17 (47.2) .638
Age, first admissiond
(mean ± SE)
1.72 (3.02) 1.60 (3.29) .476
ICU admissions
(mean ± SE)
0.03 (0.17)e 0 (0.0) .317
Respiratory admissions
(mean ± SE)
0.97 (2.13)e 0.78 (1.33) .889
Respiratory pathogens
(mean ± SE)
0.08 (0.28)f 0.08 (0.28) 1.000
Adulthood
Age, first admissiong
(mean ± SE)
15.1 (13.6) 26.9 (9.4) .001
Age, first respiratory
(mean ± SE)
19.3 (17.2)e 36.9 (10.1) <.001
ICU admissions
(mean ± SE)
0.2 (0.6)e 0.1 (0.3) .694
Respiratory admissions
(mean ± SE)
3.1 (6.0) 2.3 (2.9) .889
Abbreviations: HTLV-1, human T-lymphotropic virus type 1; ICU, intensive care
unit; SE, standard error.
a Continuous variables are summarized using mean and SE as appropriate.
b Twenty cases and 17 controls were admitted in childhood.
c Infective (infective dermatitis, 3; complicated strongyloidiasis, 2) and
inflammatory (uveitis, 1; pericarditis, 1) conditions likely to be HTLV-1
associated.
d Age of Admission with any condition in childhood.
e Admission with a respiratory condition prior to diagnosis with bronchiectasis.
f Number of respiratory pathogens isolated in childhood prior to diagnosis with
bronchiectasis.
g Age of admission with any condition after the age of 14 years.
6 • OFID • Einsiedel et al
is predominantly derived from infected lymphocytes [15]. Like-
wise, a marked inflammatory response follows the infiltration
of HTLV-1-infected lymphocytes into the pulmonary parenchy-
ma. Increased recovery of infected lymphocytes from bronchoal-
veolar lavage (BAL) fluid has been reported in patients with
HAM/TSP [27–29] and in otherwise healthy carriers [30]. The
high HTLV-1 PVL [30] of these cells was correlated with that
of peripheral blood mononuclear cells [30]. The presence of
HTLV-1-infected lymphocytes in BAL fluid is associated with in-
creased HTLV-1 tax/rex mRNA expression in vivo [31, 32], a
proinflammatory milieu [32], and an HTLV-1-specific cytotoxic
T cell-mediated inflammatory response among patients with
HTLV-1-associated interstitial pneumonitis [33].
In the present study, the median HTLV-1 PVL among cases
was more than 100-fold greater than controls, and the HTLV-1
PVL was correlated with the extent of radiologically defined
pulmonary injury. These findings suggest that an HTLV-1-
mediated inflammatory process contributes to the development
of bronchiectasis in our study population. Cases were also more
likely to have been admitted with other HTLV-1-associated
conditions including infective dermatitis and were more likely
to be Strongyloides seropositive. Childhood infective dermatitis
is associated with a high HTLV-1 PVL and with childhood
bronchiectasis in Jamaica [34]. Although an association be-
tween HTLV-1 infection and Strongyloides seropositivity has
not been consistently shown [35, 36], the risk of symptomatic
strongyloidiasis is increased among subjects with high HTLV-
1 PVL [37]. The clinical markers of HTLV-1-associated bron-
chiectasis described here are therefore those HTLV-1-related
diseases that are associated with high HTLV-1 PVL in other
populations. Nevertheless, the primary clinical manifestation
of HTLV-1 infection in our cohort was severe pulmonary dis-
ease, and this is uncommon among HTLV-1 carriers in other
developed countries [12, 13]. In our socially disadvantaged
study population, progressive lung disease might result from re-
peated LRTI in HTLV-1 carriers with preexisting HTLV-1-
associated pulmonary injury.
A number of limitations should be noted. First, recruitment
occurred over a relatively short period and was confined to pa-
tients admitted with bronchiectasis for >48 h. Therefore, our
findings may not be relevant to patients with less severe disease
who are primarily managed in the community. We were also
unable to enroll all patients in the ASH bronchiectasis cohort,
raising the possibility of selection bias. However, team members
were blinded to HTLV-1 serostatus, and there was no difference
in HTLV-1 seropositivity rates between eligible patients and
those who were recruited to the study. A further limitation
lies in the retrospective collection of data relating to previous
admissions. The diagnostic confirmation of clinical conditions,
such as infective dermatitis, that had resolved prior to recruit-
ment was therefore not possible. Finally, some patients with
limited bronchiectasis may have been recruited as controls be-
cause chest x-rays, which have a low sensitivity for detecting
early bronchiectasis, were used to exclude pulmonary disease
in this group. Although this might contribute to the high
HTLV-1 seropositivity rate in our control group (42%), this
most likely reflects the cohort’s age and the matching of controls
to cases by ethno-geographic origin [1].
Among the Indigenous population of central Australia, HTLV-
1 infection is associated with multilobar bronchiectasis, which
carries a poor prognosis [14]. The present study suggests that
an HTLV-1-mediated inflammatory process is etiologically
associated with this life-threatening condition. Human T-
lymphotropic virus type 1 carriers with bronchiectasis had higher
HTLV-1 PVLs, which were correlated with the extent of pulmo-
nary injury, and other manifestations of HTLV-1 infection were
only found among cases. In contrast to other developed coun-
tries, pulmonary disease was the predominant clinical manifesta-
tion of HTLV-1 infection in our socially disadvantaged study
population. In this setting, progression to clinically significant
bronchiectasis might result from further pulmonary injury after
recurrent LRTIs. Further studies are required to determine
whether HTLV-1 infection contributes to the development of
bronchiectasis in other socially disadvantaged settings.
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